about
Addressing the challenges of low clearance in drug researchBioPPSy: An Open-Source Platform for QSAR/QSPR AnalysisMultifunctional polymeric micelles for delivery of drugs and siRNA.Design, synthesis, and characterization of novel apigenin analogues that suppress pancreatic stellate cell proliferation in vitro and associated pancreatic fibrosis in vivo.Driving efficiency in a high-throughput metabolic stability assay through a generic high-resolution accurate mass method and automated data mining.Combining 2D and 3D in silico methods for rapid selection of potential PDE5 inhibitors from multimillion compounds' repositories: biological evaluation.Forward chemical genetic screens in Arabidopsis identify genes that influence sensitivity to the phytotoxic compound sulfamethoxazoleCombination of 2D/3D ligand-based similarity search in rapid virtual screening from multimillion compound repositories. Selection and biological evaluation of potential PDE4 and PDE5 inhibitors.Combination of Pharmacophore Matching, 2D Similarity Search, and In Vitro Biological Assays in the Selection of Potential 5-HT6 Antagonists from Large Commercial Repositories.Synthesis, characterization, and pharmacological evaluation of novel azolo- and azinothiazinones containing 2,4-dihydroxyphenyl substituent as anticancer agents.Growing PAINS in academic drug discovery.Pharmacological activity of retinoic acid receptor alpha-selective antagonists in vitro and in vivo.Genomes to hits in silico - a country path today, a highway tomorrow: a case study of chikungunya.Partitioning into Colloidal Structures of Fasted State Intestinal Fluid Studied by Molecular Dynamics Simulations.The use of small-molecule structures to complement protein-ligand crystal structures in drug discoveryIntestinal solubility and absorption of poorly water soluble compounds: predictions, challenges and solutions.The role of the carrier in the formulation of pharmaceutical solid dispersions. Part I: crystalline and semi-crystalline carriers.Toward the establishment of standardized in vitro tests for lipid-based formulations. 5. Lipolysis of representative formulations by gastric lipase.Identification of potential trypanothione reductase inhibitors among commercially available [Formula: see text]-carboline derivatives using chemical space, lead-like and drug-like filters, pharmacophore models and molecular docking.Towards a more robust approach to selecting and prosecuting promising targets and compounds.Mouse tissue distribution and persistence of the food-born fusariotoxins Enniatin B and Beauvericin.Probabilistic Approach to Generating MPOs and Its Application as a Scoring Function for CNS Drugs.Novel dihydropyrimidine derivatives as potential HDAC inhibitors: in silico study.Characterization of the intrinsic activity for a novel class of cannabinoid receptor ligands: Indole quinuclidine analogs.A comparison of in vitro ADME properties and pharmacokinetics of azithromycin and selected 15-membered ring macrolides in rodents.Development of a high-speed, multiplexed sample-delivery instrument for LC-MS/MS bioanalysis.Synergistic Effect of Polyvinyl Alcohol and Copovidone in Itraconazole Amorphous Solid Dispersions.Characterization of Supersaturated Danazol Solutions - Impact of Polymers on Solution Properties and Phase Transitions.Tailoring supersaturation from amorphous solid dispersions.
P2860
Q26998665-1B16E026-AD8D-48F8-8380-3DA010000E7CQ28553456-10A6B16F-BE62-47E6-BCC1-E52F42A68FB5Q30438973-69790C68-C7AC-4473-9D6D-B614EBC77C82Q33880435-921B7481-F1DF-4CB9-A799-C95D7F47647AQ34014643-FCEAC438-8720-44FC-B46F-47C9FDC5A10EQ34030603-BD57BEA0-EEC1-4841-B2E6-F5D54CCD84F9Q34486918-AFA26CB0-57D0-4969-AF01-9D8B6F04BB98Q35176982-2504880B-1972-4B1D-8A49-91946F4305D7Q35590479-A20F3FC5-DB48-4521-ACB0-35FD0452A62BQ35837669-F945DF70-0666-4AAD-A509-C779D89623C9Q36886292-C7D9717F-9C85-4F7D-8BCB-10756E9FD961Q37163356-5A34D632-3B58-44EC-AC4D-8A861F3C5122Q37319331-D31E95A7-D9A1-4B27-B7AB-64F71ADFED13Q37610577-A586EBB0-B872-4810-880F-0C397858185CQ37698627-D94299F5-75B7-442D-9285-509C97230822Q38575611-83C9B0C1-51E4-4EF3-A5F4-01E8E27BDEC0Q38870191-BC2DC29F-215C-4C14-A3D1-9DDC2A7415F4Q39117775-84471B25-0024-4392-8087-97777F3C13D8Q39404983-1EC33345-6714-4082-B9C9-5E8F7CA91226Q39915228-7A562778-B66C-42EF-95B0-30F31674AD91Q39985694-ADC08C91-F403-4408-A961-ADB08326C4CDQ41957171-803F793E-C520-4D1E-B606-FEA6CF745100Q42702066-709B1D39-B973-4FAE-8DA8-895C8A273AC4Q43214296-6C26FA7F-548F-4568-9247-5F86F9557725Q45718671-DD7B2518-1686-4451-9D6D-498D7723F925Q45938317-85BA1EBF-6202-45A6-81EC-1373D68E4C58Q47729955-0031B415-C67D-445B-8E14-2B37497EE77BQ48627689-BCBB00DB-F333-4C88-8BDC-9BFBBAD887FCQ53410930-F3F8DDFB-0BB9-405D-9709-0D8BF7759BD5
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Drug-like property concepts in pharmaceutical design.
@en
Drug-like property concepts in pharmaceutical design.
@nl
type
label
Drug-like property concepts in pharmaceutical design.
@en
Drug-like property concepts in pharmaceutical design.
@nl
prefLabel
Drug-like property concepts in pharmaceutical design.
@en
Drug-like property concepts in pharmaceutical design.
@nl
P2093
P1476
Drug-like property concepts in pharmaceutical design.
@en
P2093
Edward H Kerns
Guy T Carter
P304
P356
10.2174/138161209788682479
P577
2009-01-01T00:00:00Z